沙利度胺联合TP化疗方案治疗晚期食管癌的临床效果  

Clinical effects of Thalidomide combined with TP chemotherapy in patients with advanced esophageal cancer

作　　者：梁文昌 王俊生[1] 周静[1] LIANG Wenchang;WANG Junsheng;ZHOU Jing(Anyang Cancer Hospital,Anyang 455000 Henan,China)

机构地区：[1]安阳市肿瘤医院,河南安阳455000

出　　处：《中国民康医学》2019年第2期10-11,共2页Medical Journal of Chinese People’s Health

摘　　要：目的:观察沙利度胺联合化疗方案治疗晚期食管癌的临床效果。方法:选取晚期食管癌患者96例作为研究对象。采用随机数字表法分为观察组和对照组各48例,观察组实施沙利度胺联合TP化疗,对照组实施单纯TP化疗。比较两组治疗效果及不良反应发生情况。结果:观察组的总有效率和疾病控制率分别为45.83%(22/48)和91.67%(44/48),高于对照组的31.25%(15/48)和75.00%(36/48),差异有统计学意义(P<0.05);观察组不良反应发生率为8.33%(4/48),低于对照组的20.83%(10/48),差异有统计学意义(P<0.05)。结论:实施沙利度胺联合TP化疗方案治疗晚期食管癌的临床效果优于单纯TP化疗治疗。Objective:To observe clinical effects of Thalidomide combined with chemotherapy in treatment of patients with advanced esophageal cancer.Methods:96 patients with advanced esophageal cancer were selected as the subjects.They were divided into observation group and control group according to the random number table method,48 cases in each.The observation group was treated with Thalidomide combined with TP chemotherapy,while the control group was treated with TP alone.The treatment effects and adverse reactions of the two groups were compared.Results:The total effective rate and disease control rate of the observation group were 45.83%(22/48)and 91.67%(44/48),respectively,which were higher than the control group of 31.25%(15/48)and 75.00%(36/48),respectively,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 8.33%(4/48),which was lower than that in the control group(20.83%,10/48),and the difference was statistically significant(P<0.05).Conclusions:Thalidomide combined with TP chemotherapy in the treatment of the patients with advanced esophageal cancer is superior to single TP chemotherapy.

关 键 词：晚期 食管癌 沙利度胺 化疗 

分 类 号：R735.1[医药卫生—肿瘤]